Business
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasd
About this update from Vaccinex, Inc.
[{"type":"image","alt":"Vaccinex, Inc.","displaySize":"","headline":null,"caption":"Vaccinex, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/878764eb3c52e76763f7259bf60e5828"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e4mMLmu0Yt.1UeEn0MezUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/878764eb3c52e76763f7259bf60e5828","width":300,"height":80}},"lazy":false},{"type":"text","content":"ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.","length":585,"tagName":"p"},{"type":"text","content":"Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.","length":156,"tagName":"p"},{"type":"text","content":"The Company’s decision to delist follows its receipt of notice dated December 16, 2024, that the Nasdaq Hearings Panel had determined to delist the Company’s securities from Nasdaq, and the subsequent suspension of trading. Nasdaq would have otherwise filed a Form 25 in due course.","length":282,"tagName":"p"},{"type":"text","content":"The Company plans to continue to focus on development of its lead product, pepinemab, to treat Alzheimer’s disease and cancer through partnerships, grants and other financing avenues.","length":183,"tagName":"p"},{"type":"text","content":"About Vaccinex Inc.","length":24,"tagName":"p"},{"type":"text","content":"Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brai...